Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

27.02
-0.1000-0.37%
Post-market: 26.50-0.5200-1.92%17:43 EDT
Volume:335.73K
Turnover:8.92M
Market Cap:803.34M
PE:-32.42
High:27.03
Open:26.81
Low:25.76
Close:27.12
52wk High:44.28
52wk Low:14.59
Shares:29.73M
Float Shares:25.11M
Volume Ratio:0.62
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8334
EPS(LYR):-0.8334
ROE:-5.21%
ROA:-2.56%
PB:1.71
PE(LYR):-32.42

Loading ...

Castle Biosciences Inc : Leerink Partners Raises Target Price to $40 From $35

THOMSON REUTERS
·
Nov 04, 2025

Castle Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 04, 2025

Castle Biosciences raises FY25 revenue view to $327M-$335M from $310M-$320M

TIPRANKS
·
Nov 04, 2025

Stock Track | Castle Biosciences Soars 5.48% on Strong Q3 Revenue Beat

Stock Track
·
Nov 04, 2025

BRIEF-Castle Biosciences Q3 Revenue USD 83.043 Million Vs. IBES Estimate USD 71.2 Million

Reuters
·
Nov 04, 2025

Castle Biosciences Q3 Pretax Profit USD -386 Thousand

THOMSON REUTERS
·
Nov 04, 2025

Castle Biosciences Inc - Raises Full-Year 2025 Revenue Guidance to $327-335 Million

THOMSON REUTERS
·
Nov 04, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 03, 2025

Castle Biosciences to Present at Stephens Annual Investment Conference

Reuters
·
Oct 28, 2025

Castle Biosciences announces new data on TissueCypher Barrett’s Esophagus test

TIPRANKS
·
Oct 27, 2025

BRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus

Reuters
·
Oct 27, 2025

Castle Biosciences Inc - Tissuecypher Shows 34% and 62% Five-Year Progression Risk

THOMSON REUTERS
·
Oct 27, 2025

New Data at American College of Gastroenterology Annual Meeting Show Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

THOMSON REUTERS
·
Oct 27, 2025

Castle Biosciences Unveils Data Showing Pipeline Test Guides Personalized Atopic Dermatitis Treatment

Reuters
·
Oct 24, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Oct 23, 2025

Castle Biosciences Inc. to Announce Third Quarter 2025 Financial Results

Reuters
·
Oct 13, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Disposal of Common Shares

Reuters
·
Oct 07, 2025

Press Release: Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Dow Jones
·
Oct 02, 2025

Castle Biosciences Inc. CEO Derek J. Maetzold Reports Disposal of Common Shares

Reuters
·
Sep 24, 2025

Scibase Receives Initial Order For Clinical Study From Castle Biosciences

Reuters
·
Sep 23, 2025